Eric P. Palmer
Known title: President & CEO, EvernorthCIK: 0001710190
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cigna Focuses on Data-Driven Care and Valuation Metrics. Recent coverage highlights Cigna's strategic shift toward data-driven care through its Health Sense initiative, positioning it as a key differentiator in the healthcare sector. Analysts are also examining the stock's valuation, noting a forward P/E that suggests value despite ongoing earnings risks. With the stock trading near its 52-week high, these developments provide context for its current market position relative to peers like UnitedHealth.
Transaction History
| LFST | ▲ Buy | Grant | 17,746 | $0 | 7/2/2026 | View on chart |
| LFST | ▲ Buy | Grant | 71,428 | $0 | 6/11/2025 | View on chart |
| CI | ▲ Buy | Grant | 15,982 | $0 | 2/28/2025 | View on chart |
| CI | ▼ Sell | Tax Withholding | 2,083 | $637K | 2/28/2025 | View on chart |
| CI | ▼ Sell | Tax Withholding | 7,407 | $2.3M | 2/28/2025 | View on chart |
| CI | ▲ Buy | Grant | 5,395 | $0 | 2/28/2025 | View on chart |
| CI | ▼ Sell | Gift | 50 | $0 | 11/15/2024 | View on chart |
| CI | ▼ Sell | Tax Withholding | 2,710 | $903K | 3/1/2024 | View on chart |
| CI | ▼ Sell | Tax Withholding | 5,928 | $2.0M | 3/1/2024 | View on chart |
| CI | ▲ Buy | Grant | 12,792 | $0 | 3/1/2024 | View on chart |
| CI | ▲ Buy | Grant | 5,127 | $0 | 2/28/2024 | View on chart |
| CI | ▼ Sell | Gift | 200 | $0 | 2/15/2024 | View on chart |
| CI | ▼ Sell | Gift | 312 | $0 | 2/15/2024 | View on chart |
| CI | ▼ Sell | Gift | 312 | $0 | 2/15/2024 | View on chart |
| CI | ▲ Buy | Option Exercise | 905 | $135K | 2/14/2024 | View on chart |
| CI | ▼ Sell | Open Market | 6,083 | $2.1M | 2/13/2024 | View on chart |
| CI | ▲ Buy | Option Exercise | 5,168 | $771K | 2/13/2024 | View on chart |
| CI | ▼ Sell | Open Market | 1,017 | $341K | 2/9/2024 | View on chart |
| CI | ▲ Buy | Option Exercise | 1,017 | $142K | 2/5/2024 | View on chart |
| CI | ▲ Buy | Option Exercise | 5,684 | $791K | 2/2/2024 | View on chart |
| CI | ▼ Sell | Open Market | 5,684 | $1.8M | 2/2/2024 | View on chart |
| CI | ▼ Sell | Gift | 390 | $0 | 5/8/2023 | View on chart |
| CI | ▼ Sell | Gift | 390 | $0 | 5/8/2023 | View on chart |
| CI | ▼ Sell | Tax Withholding | 1,889 | $547K | 3/1/2023 | View on chart |
| CI | ▼ Sell | Tax Withholding | 572 | $168K | 2/24/2023 | View on chart |
| CI | ▼ Sell | Tax Withholding | 4,992 | $1.5M | 2/24/2023 | View on chart |
| CI | ▲ Buy | Grant | 11,265 | $0 | 2/24/2023 | View on chart |
| CI | ▲ Buy | Grant | 5,304 | $0 | 2/22/2023 | View on chart |
| CI | ▼ Sell | Open Market | 4,000 | $1.2M | 10/14/2022 | View on chart |
| CI | ▲ Buy | Option Exercise | 860 | $104K | 7/8/2022 | View on chart |
| CI | ▲ Buy | Option Exercise | 5,557 | $672K | 7/7/2022 | View on chart |
| CI | ▼ Sell | Open Market | 6,521 | $1.8M | 7/7/2022 | View on chart |
| CI | ▲ Buy | Option Exercise | 1,311 | $102K | 4/7/2022 | View on chart |
| CI | ▲ Buy | Option Exercise | 6,656 | $519K | 4/6/2022 | View on chart |
| CI | ▼ Sell | Open Market | 8,126 | $2.0M | 4/6/2022 | View on chart |
| CI | ▼ Sell | Gift | 400 | $0 | 3/3/2022 | View on chart |
| CI | ▼ Sell | Gift | 400 | $0 | 3/3/2022 | View on chart |
| CI | ▼ Sell | Tax Withholding | 932 | $220K | 3/1/2022 | View on chart |
| CI | ▼ Sell | Tax Withholding | 2,363 | $543K | 2/25/2022 | View on chart |
| CI | ▼ Sell | Tax Withholding | 1,119 | $257K | 2/25/2022 | View on chart |
| CI | ▲ Buy | Grant | 5,352 | $0 | 2/25/2022 | View on chart |
| CI | ▲ Buy | Grant | 6,195 | $0 | 2/23/2022 | View on chart |
| CI | ▼ Sell | Gift | 335 | $0 | 5/18/2021 | View on chart |
| CI | ▼ Sell | Gift | 335 | $0 | 5/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Keybanc Raises LifeStance Health Price Target to $15
Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.
Keybanc Raises LifeStance Health Price Target to $15. Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.